Los Angeles Capital Management
APGE icon

Los Angeles Capital Management’s Apogee Therapeutics APGE Stock Holding History

Los Angeles Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.4K Sell
136
-354
-72% -$25.7K ﹤0.01% 1912
2025
Q4 		$27.5K Buy
+490
New +$30.9K ﹤0.01% 1772
2024
Q4 		– Sell
-6,534
Closed -$384K – 1110
2024
Q3 		$384K Sell
6,534
-370
-5% -$17.7K ﹤0.01% 933
2024
Q2 		$272K Buy
+6,904
New +$335K ﹤0.01% 1047

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Los Angeles Capital Management's APGE Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Apogee Therapeutics (APGE) stake by 72% in Q1 2026, selling an estimated $25.7K and leaving 136 shares worth $11.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1912.

Los Angeles Capital Management first reported a position in APGE in Q2 2024 and has held it in 4 quarters since. The position peaked at $384K in Q3 2024. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Los Angeles Capital Management held 136 shares of Apogee Therapeutics worth $11.4K as of Q1 2026.
  • Los Angeles Capital Management sold 354 Apogee Therapeutics shares in Q1 2026, an estimated $25.7K.
  • Apogee Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1912 holding.
  • Los Angeles Capital Management first reported a position in Apogee Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • Los Angeles Capital Management's Apogee Therapeutics position peaked at $384K in Q3 2024.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.